Y-mAbs Therapeutics Reiterates FY23 Revenue $80M-$85M Vs $82.79M Est
Portfolio Pulse from Benzinga Newsdesk
Y-mAbs Therapeutics has reiterated its FY23 revenue guidance in the range of $80M-$85M, which is in line with the estimated $82.79M.
August 10, 2023 | 8:28 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Y-mAbs Therapeutics' reaffirmed FY23 revenue guidance aligns with the market estimate, indicating stable financial expectations.
Y-mAbs Therapeutics' reaffirmed revenue guidance for FY23 is in line with market estimates. This suggests that the company's financial outlook is stable and in line with market expectations, which is likely to have a neutral impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100